BioSpace· Heather McKenzie·· 4 小时前评分63
Tango Therapeutics的vopimetostat联合daraxonrasib胰腺癌ORR降至82%，仍拟推进三期试验
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
导读
Tango Therapeutics的vopimetostat联合daraxonrasib在胰腺癌Phase 1/2研究中取得82% ORR，低于此前12例报告的92%。
来源：BioSpace · biospace.com